| Autor: |
Filev R; Department of Nephrology, Internal Disease Clinic, University Hospital 'Saint Anna', 1750 Sofia, Bulgaria.; Faculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria., Lyubomirova M; Department of Nephrology, Internal Disease Clinic, University Hospital 'Saint Anna', 1750 Sofia, Bulgaria.; Faculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria., Bogov B; Department of Nephrology, Internal Disease Clinic, University Hospital 'Saint Anna', 1750 Sofia, Bulgaria.; Faculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria., Kalinov K; Head Biometrics Group, Comac-Medical Ltd., 1404 Sofia, Bulgaria., Hristova J; Faculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria.; Department of Clinical Laboratory, University Hospital 'Alexandrovska', 1431 Sofia, Bulgaria., Svinarov D; Faculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria.; Department of Clinical Laboratory, University Hospital 'Alexandrovska', 1431 Sofia, Bulgaria., Garev A; Faculty of Medicine, Medical University Sofia, 1504 Sofia, Bulgaria.; Cardiology Department, University Hospital 'Alexandrovska', 1431 Sofia, Bulgaria., Rostaing L; Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, 38043 Grenoble, France.; Internal Disease Department, Grenoble Alpes University, 38043 Grenoble, France. |
| Abstrakt: |
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant health concern, particularly for patients with chronic kidney disease (CKD). This study investigates the long-term outcomes of individuals with CKD who were infected with COVID-19, focusing on their health status over a three-year period post-infection. Data were collected from both CKD and non-CKD patients who survived SARS-CoV-2 infection and were followed for three years as part of a research study on the impact, prognosis, and consequences of COVID-19 infection in CKD patients. In this prospective cohort study, we analyzed clinical records, laboratory findings, and patient-reported outcomes assessed at intervals during follow-up. The results indicated no permanent changes in renal function in any of the groups analyzed, although patients without CKD exhibited faster recovery over time. Furthermore, we examined the effect of RAAS-blocker therapy over time, finding no influence on PASC symptoms or renal function recovery. Regarding PASC symptoms, most patients recovered within a short period, but some required prolonged follow-up and specialized post-recovery management. Following up with patients in the post-COVID-19 period is crucial, as there is still insufficient information and evidence regarding the long-term effects, particularly in relation to CKD. |
